Back to today’s briefing

Story perspectives

Bayer Launches Major Trials for Parkinson's Therapies

9/24/2025

40 9

Summary

Story summary

Bayer begins pivotal Phase III trial for bemdaneprocel and advances AB-1005 in Phase II with European participants.
Both therapies are developed with Bayer subsidiaries BlueRock Therapeutics and AskBio for moderate-stage Parkinson's.
The exPDite-2 trial aims to enroll around 100 patients to test restoration of dopamine-producing neurons.
Bayer plans a Berlin facility to support cell and gene therapy, expected completion in 2028.

1 of 1

Story summary

Bayer begins pivotal Phase III trial for bemdaneprocel and advances AB-1005 in Phase II with European participants.
Both therapies are developed with Bayer subsidiaries BlueRock Therapeutics and AskBio for moderate-stage Parkinson's.
The exPDite-2 trial aims to enroll around 100 patients to test restoration of dopamine-producing neurons.
Bayer plans a Berlin facility to support cell and gene therapy, expected completion in 2028.